Zealand Pharma enters $1.25bn obesity AI collaboration
Danish biotechnology company Zealand Pharma has announced a multi-target strategic collaboration with US-based Generate Biomedicines to design and develop novel protein therapeutics for obesity and other metabolic diseases. Under the terms of the agreement, Generate will receive an upfront payment of $30m and up to $35m in early preclinical milestones for the first two programmes. Generate is also eligible to…
Roche acquiring PathAI in billion-dollar deal
Swiss healthcare giant Roche has entered into a definitive merger agreement to acquire the digital pathology specialist PathAI in a transaction valued at up to $1.05 billion. The deal involves a $750 million upfront cash payment and up to $300 million in performance and regulatory milestones. Expected to close in the second half of 2026, the acquisition will fold the…